Tenofovir-induced kidney injury

Bibliography

• Viread package insert. Physicians Desk reference (61 edn). Thompson PDR, Montvale NJ, USA (2007):1301-1308.
   Google Scholar
• CHAPMAN T, MCGAVIN J, NOBLE S: Tenofovir disoproxil fumarate. Drugs (2003) 63(15):1597-1608.
   PubMed Web of Science ®Google Scholar
• IZZEDINE H, LAUNAY-VACHER V, JULLIEN V, AYMARD G, DUVIVIER C, DERAY G: Pharmacokinetics of tenofovir in haemodialysis. Nephrol. Dial. Transplant. (2003) 18:1931-1933.
   PubMed Web of Science ®Google Scholar
• HO ES, LIN DC, MENDELL DB, CHILAR T: Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. (2000) 11:338-393.
   Web of Science ®Google Scholar
• CIHLAR T, HO ES, LIN DC, MULATO AS: Human renal organic anion transporter 1 (hOAT1) and its role in nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids (2001) 20(4-7):641-648.
   PubMed Web of Science ®Google Scholar
• RAY AS, CIHLAR T, ROBINSON KL et al.: Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. (2006) 50(10):3297-3304.
   PubMed Web of Science ®Google Scholar
• SERVAIS A, LECHAT P, ZAHR N et al.: Tubular transporters OAT1 and MRP2 and clearance of adefovir. Nephrol. Ther. (2005) 1(5):296-300.
   PubMedGoogle Scholar
• Reyataz package insert. Physicians Desk reference (61 edition). Thompson PDR, Montvale NJ, USA (2007):921-930.
   Google Scholar
• Kaletra package insert. Physicians Desk reference (61 edition). Thompson PDR, Montvale NJ, USA (2007):476-486.
   Google Scholar
• KEARNEY BP, FLAHERTY JF, SAYRE JR et al.: A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and lamivudine or didanosine. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina (2001).
   Google Scholar
• KEARNEY BP, DAMIE B, PLUMMER A et al.: Tenofovir DF (TDF) and didanosine EC (ddI EC): investigation of pharmacokinetic (PD) drug-drug and drug-food interactions. XIV International AIDS Conference. Barcelona, Spain (2002):LBPE9026.
   Google Scholar
• KEARNEY BP, ISAACSON E, SAYRE J et al.: Didanosine and tenofovir DF drug–drug interaction: assessment of didanosine dose reduction. 10th Conference on Retroviruses and Opportunistic Infections. Boston, USA (2003):533.
   Google Scholar
• BARRIOS A, RENDON A, NEGREDO E et al.: Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. AIDS (2005) 19:569-575.
   PubMed Web of Science ®Google Scholar
• HAMMER SM, SAAG MS, SCHECHTER et al.: Treatment for adult HIV infection 2006: recommendations of the international AIDS society-USA panel. JAMA (2006) 296:827-843.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY R, RUANE P, MYERS R et al.: Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS (2002) 16:1257-1263.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, STASZEWSKI S, POZNIAK A et al.: Efficacy and safety of tenofovir DF versus stavudine in combination therapy in antiretroviral-naïve patients. JAMA (2004) 292(2):191-201.
   PubMed Web of Science ®Google Scholar
• GALLANT JE, DEJESUS E, ARRIBAS JR et al.: Tenofovir df, emtricitabine, and efavirenz versus zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med. (2006) 354:251-260.
   PubMed Web of Science ®Google Scholar
• LAESSIG KA, LEWIS LL, HAMMERSTROM TS: Tenofovir DF and emtricitabine versus zidovudine and lamivudine. N. Engl. J. Med. (2006) 354:2506-2507.
   PubMedGoogle Scholar
• WHITE KL, CHEN JM, FENG JY et al.: The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir. Ther. (2006) 11:155-163.
   PubMed Web of Science ®Google Scholar
• ROSS L, PARKIN N, CHAPPEY C et al.: Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS (2004) 18:1691-1696.
   PubMed Web of Science ®Google Scholar
• LEVY V, GRANT RM: Antiretroviral therapy for hepatitis B virus-HIV coinfected patients: promises and pitfalls. Clin. Infect. Dis. (2006) 43:904-910.
   PubMed Web of Science ®Google Scholar
• RIFKIN G, PERAZELLA M: Tenofovir-associated nephrotoxicity: Fancoi syndrome and renal failure. Am. J. Med. (2004) 117:282-284.
   PubMed Web of Science ®Google Scholar
• ORTIZ A, JUSTO P, SANZ A et al.: Tubular cell apoptosis and cidofovir-induced acute renal failure. Antivir. Ther. (2005) 10(1):185-190.
   PubMed Web of Science ®Google Scholar
• TANJI N, TANJI K, KAMBHAM N, MARKOWITZ GS, BELL A, D’AGATI VD: Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum. Pathol. (2001) 32(7):734-740.
   PubMed Web of Science ®Google Scholar
• BENDELE R, RICHARDSON F: Adefovir nephrotoxicity and mitochondrial DNA depletion. Hum. Pathol. (2002) 33(5):574.
   PubMedGoogle Scholar
• FOREMAN JW: Fanconi’s syndrome and other proximal tubule disorders. In: Comprehensive Clinical Nephrology (volume 2). Johnson R, Feehally J (Eds), Mosby, New York, USA (2003):653-664.
   Google Scholar
• CIHLAR T, BIRDUS G, GREENWALT D, HITCHCOCK M: Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antivir. Res. (2002) 54:37-45.
   PubMed Web of Science ®Google Scholar
• BIRKUS G, HITCHCOCK M, CIHLAR T: Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (2002) 46(3):716-723.
   PubMed Web of Science ®Google Scholar
• BIESECKER G, KARIMI S, DESJARDINS J et al.: Evaluation of mitochondrial DNA content and enzyme levels in tenofovir DF-treated rats, rhesus monkeys and woodchucks. Antivi. Res. (2003) 58:217-225.
   PubMed Web of Science ®Google Scholar
• VAN ROMPAY K, BRIGNOLO L, MEYER D et al.: Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob. Agents Chemother. (2004) 48(5):1469-1487.
   PubMed Web of Science ®Google Scholar
• IZZEDINE H, HULOT J, VITTECOQ D et al.: Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. (2005) 20:743-746.
   PubMed Web of Science ®Google Scholar
• PADILLA S, GUTIERREA F, MASIA M, CANOVAS V, OROZCO C: Low frequency of renal function impairment during one-year of therapy with tenofovir-containing regimens in the real-world: a case-control study. AIDS Patient Care STDS (2005) 19:421-424.
   PubMed Web of Science ®Google Scholar
• ANTONIOU T, RABOUD JM, CHIRHIN S et al.: Incidence of and risk factors for tenofovir-induced nephrotoxicity: a retrospective cohort study. HIV Med. (2005) 6:284-290.
   PubMed Web of Science ®Google Scholar
• JONES R, STEBBING J, NELSON M et al.: Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently. J. Acquir. Immune Defic. Syndr. (2004) 37(4):1489-1495.
   PubMed Web of Science ®Google Scholar
• WINSTON A, AMIN J, MALLON PWF et al.: Minor changes in calculated creatinine clearance and anion-gap are associated wit tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. (2006) 7:105-111.
   PubMed Web of Science ®Google Scholar
• GALLANT J, PARISH M, KERULY J, MOORE R: Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin. Infect. Dis. (2005) 40:1194-1198.
   PubMed Web of Science ®Google Scholar
• GALLANT J, PARISH M, KERULY J, MOORE R: Tenofovir and changes in renal function. Clin. Infect. Dis. (2005) 41:571.
   PubMed Web of Science ®Google Scholar
• MAUSS S, BERGER F, SCHMUTZ G: Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS (2005) 19:93-99.
   PubMed Web of Science ®Google Scholar
• BUCHACZ D, BROOKS JT, TONG T et al.: Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy. HIV Med. (2006) 7:451-456.
   PubMed Web of Science ®Google Scholar
• DAY S, LEAKE DATE H, BANNISTER A, HANKINS M, FISHER M: Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice. J. Acquir. Immune Defic. Syndr. (2005) 38(3):301-304.
   PubMed Web of Science ®Google Scholar
• NELSON M, COOPER D, SCHOOLEY R et al.: The safety of tenofovir DF or the treatment of hiv infection: the first 4 years. 13th Conference on Retroviruses and Opportunistic Infections. Denver, USA (2006):781.
   Google Scholar
• ZIMMERMAN A, PIZZOFERRATO T, BEDFORD J, MORRIS A, HOFFMAN R, BRADEN G: Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions. Clin. Infect. Dis. (2006) 42:283-290.
   PubMed Web of Science ®Google Scholar
• MALIK A, ABRAHAM P, MALIK N: Acute renal failure and fanconi syndrome in an AIDS patient on tenofovir treatment-case report and review of literature. J. Infect. (2005) 51:e61-e65.
   PubMedGoogle Scholar
• PEYRIERE H, REYNES J, ROUANET I et al.: Renal tubular dysfunction associated with tenofovir therapy. J. Acquir. Immune Defic. Syndr. (2004) 35:269-273.
   PubMed Web of Science ®Google Scholar
• KARRAS A, LAFAURIE M, FURCO A et al.: Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin. Infect. Dis. (2003) 36(15):1070-1073.
   PubMed Web of Science ®Google Scholar
• ROLLOT F, NAZL E, CHAUVELOT-MOACHON L et al.: Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir–ritonavir–didanosine. Clin. Infect. Dis. (2003) 37:e174-e176.
   PubMed Web of Science ®Google Scholar
• VERHELST D, MONGE M, MEYNARD J et al.: Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am. J. Kidney Dis. (2002) 40(6):1331-1333.
   PubMed Web of Science ®Google Scholar
• CICCONI P, BONGIOVANNI M, MELZI S et al.: Nephrolithiasis and hydronephrosis in an HIV-infected man receiving tenofovir. Int. J. Antimicrob. Agents (2004) 24:86-87.
   Google Scholar
• JEFFERSON A, ZAGER R: Causes of acute renal failure. In: Comprehensive Clinical Nephrology (volume 2). Johnson R, Feehally J (Eds), Mosby, New York, USA (2003):207-224.
   Google Scholar
• PARSONAGE MJ, WILKINS EGL, SNOWDEN N, ISSA BG, SAVAGE MW: The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Med. (2005) 6:341-346.
   PubMed Web of Science ®Google Scholar
• CREPUT C, GONZALEZ-CANALI G, HILL G, PIKETTY C, KAZATCHKINE M, NOCHY D: Renal lesions in HIV-1-positive patients treated with tenofovir. AIDS (2003) 17(6):935-937.
   PubMed Web of Science ®Google Scholar
• IZZEDINE H, ISNARD-BAGNIS C, HULOT J et al.: Renal safety of tenofovir in HIV Treatment-experienced patients. AIDS (2004) 18(7):1074-1076.
   PubMed Web of Science ®Google Scholar
• LEE J, MAROSOK R: Acute tubular necrosis in a patient receiving tenofovir. AIDS (2003) 17:2543-2545.
   PubMed Web of Science ®Google Scholar
• SCHAAF B, ARIES P, KRAMME E, STEINHOFF J, DALHOFF K: Acute Renal failure associated with tenofovir treatment in a patient with acquired immunodeficiency syndrome. Clin. Infect. Dis. (2003) 37:e41-e43.
   PubMed Web of Science ®Google Scholar
• LEEN C, WAT C, NIEFORTH K: Pharmacokinetics of enfuvirtide in a patient with impaired renal function. Clin. Infect. Dis. (2004) 39:e119-e121.
   PubMed Web of Science ®Google Scholar
• HULOT JS, VILLARD E, IZZEDINE H et al.: Association between ABCC2 gene haplotypes and proximal tubulopathy-induced by tenofovir. The Annual congress of French Pharmacology Society. Montpellier, France (2006):25.
   Google Scholar
• JOHNSON MA, GATHE JC Jr, PODZAMCZER D et al.: A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J. Acquir. Immune Defic. Syndr. (2006) 43(2):153-169.
   PubMed Web of Science ®Google Scholar
• WINSTON J, SHEPP D: The role of drug interaction and monitoring in the prevention of tenofovir-associated kidney disease. Clin. Infect. Dis. (2006) 42:1657-1658.
   PubMed Web of Science ®Google Scholar
• SAUMOY M, VIDAL F, PERAIRE J et al.: Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity? AIDS (2004) 18:1741-1742.
   PubMed Web of Science ®Google Scholar
• RAY A, OSLON L, FRIDLAND A: Role of purine nucleoside phosphorylase in interactions between 2′,3′-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob. Agents Chemother. (2004) 48(4):1089-1095.
   PubMed Web of Science ®Google Scholar
• WATERS L, MAITLAND D, MOYLE G: Tenofovir and didanosine: a dangerous liaison. AIDS Read. (2005) 15(8):403-406.
   PubMedGoogle Scholar
• ISNARD-BAGNIS C, TEZENAS DU MONTCEL S et al.: Prevalence of electrolyte and acid-base disorders in HIV patients. J. Am. Soc. Nephrol. (2002) 13:448A.
   Google Scholar
• HUANG E, HEWITT RG, SHELTON M, MORSE GD: Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy (1996) 16(2):222-229.
   PubMed Web of Science ®Google Scholar
• NOORMOHAMED SE, KATSERES JK, STAPLETON JT: Poor coorelation between published methods to predict creatinine clearance and measured creatinine clearance in asymptomatic HIV infected individuals. Ren. Fail. (1998) 20(4):627-633.
   PubMed Web of Science ®Google Scholar
• GUPTA S, EUSTACE J, WINSTON J et al.: Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medical Association of the Infectious Disease society of America. Clin. Infect. Dis. (2005) 40(11):1559-1585.
   PubMed Web of Science ®Google Scholar
• KINAI E, HANABUSA H: Renal tubular toxicity associated with tenofovir assessed using urine-beta 2 microglobulin, percentage of tubular reabsorption of phosphate and alkaline phosphatase levels. AIDS (2005) 19:2031-2032.
   PubMed Web of Science ®Google Scholar
• REICHERT L, KOENE R, WETZELS J: Urinary excretion of β2-microglobulin predicts renal outcome in patients with idiopathic membranous nephropathy. J. Am. Soc. Nephrol. (1995) 6:1666-1669.
   PubMed Web of Science ®Google Scholar
• HERGET-ROSENTHAL S, POPPEN D, HUSING J et al.: Predictive value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin. Chem. (2004) 50(3):1-7.
   Google Scholar
• KIMMEL PL, UMANA WO, BOSCH JP: Abnormal urinary protein excretion in HIV-infected patients. Clin. Nephrol. (1993) 39(1):17-21.
   PubMed Web of Science ®Google Scholar
• GATANAGA H, TACHIKAWA N, KIKUCHI Y et al.: Urinary β2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses (2006) 22:744-748.
   PubMed Web of Science ®Google Scholar
• SENTENAC S, FERNANDEZ C, THUILLIER A, LECHAT P, AYMARD G: sensitive determination of tenofovir in human plasma samples using reversed-phase liquid chromatography. J. Chromatogr. B (2003) 793:317-324.
   PubMed Web of Science ®Google Scholar